Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;12(8):1211-1213.
doi: 10.1002/mdc3.70074. Epub 2025 Apr 9.

Use of and Barriers to Subcutaneous Apomorphine Pen Injections in Parkinson's Disease: A Survey by the French NS-PARK Network

Mickael Aubignat  1 , Fatma Khelifi  2 , Olivier Rascol  3 ; NS‐PARK/FCRIN Network
Collaborators, Affiliations

Use of and Barriers to Subcutaneous Apomorphine Pen Injections in Parkinson's Disease: A Survey by the French NS-PARK Network

Mickael Aubignat et al. Mov Disord Clin Pract. 2025 Aug.
No abstract available

Keywords: Parkinson's disease; apomorphine; practice.

PubMed Disclaimer

Conflict of interest statement

Ethical Compliance Statement: The authors confirm that the approval of an institutional review board was not required for this work. Informed consent was not required. They confirm that they have read the journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Funding Sources and Conflicts of Interest: The NS‐PARK/FCRIN network has received financial support from Bial to perform this survey. The authors declare that there are no funding sources or conflicts of interest relevant to this work.

Financial Disclosures for the Previous 12 Months: M.A. and F.K. have no financial disclosures. O.R. has provided scientific advice for Apopharma, Astra‐Zeneca, Bial, Biogen, Britannia, Cerevel, Contera, GE Healthcare, Ionis, Lundbeck, Merz, Neuralight, Neuroderm, ONO Pharma, Orion Pharma, Roche Therapeutics, Supernus, Thelonius Mind, Takeda, Teva, UCB, and Zambon.

References

    1. Olanow CW, Poewe W, Rascol O, Stocchi F. On‐demand therapy for OFF episodes in Parkinson's disease. Mov Disord 2021;36(10):2244–2253. 10.1002/mds.28726. - DOI - PubMed
    1. Dewey RB, Hutton JT, LeWitt PA, Factor SA. A randomized, double‐blind, placebo‐controlled trial of subcutaneously injected apomorphine for parkinsonian off‐state events. Arch Neurol 2001;58(9):1385–1392. 10.1001/archneur.58.9.1385. - DOI - PubMed
    1. Poewe W, Wenning GK. Apomorphine: an underutilized therapy for Parkinson's disease. Mov Disord Off J Mov Disord Soc 2000;15(5):789–794. 10.1002/1531-8257(200009)15:5<789::aid-mds1005>3.0.co;2-h. - DOI - PubMed
    1. Castillo‐Torres SA, Lees AJ, Merello M. Intermittent apomorphine use for off period Rescue in Parkinson's disease: a pragmatic review of over three decades of clinical experience. Mov Disord Clin Pract 2023;10(2):190–208. 10.1002/mdc3.13593. - DOI - PMC - PubMed
    1. Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double‐blind, placebo‐controlled phase 3 study. Lancet Neurol 2020;19(2):135–144. 10.1016/S1474-4422(19)30396-5. - DOI - PubMed

Grants and funding

LinkOut - more resources